Andreas Pahl

Andreas Pahl

Company: Heidelberg Pharma Research

Job title: Chief Scientific Officer


Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy 3:45 pm

Discussing a new payload with a new mode of action providing new options to fight cancer Understanding how the ATAC platform optimized the ADC technology for that payload Reviewing HDP-101 targeting BCMA; the first ATAC which cleared IND and is now in dose escalation in myeloma patientsRead more

day: day 1- pm

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.